SRNE - Why Sorrento Therapeutics Stock Bolted Higher in September
Shares of the clinical-stage biotech Sorrento Therapeutics (NASDAQ: SRNE) gained a whopping 46.1% during the month of September, according to data provided by S&P Global Market Intelligence . For comparison, the iShares Nasdaq Biotechnology ETF gained only 1.8% last month.
Why did Sorrento's stock crush the broader biotech industry over the course of September? Investors seemingly piled into this developmental biotech for two underlying reasons:
Image source: Getty Images.
For further details see:
Why Sorrento Therapeutics Stock Bolted Higher in September